Last reviewed 2026-06-10 · How we verify

Jens D Lundgren, MD — Portfolio Competitive Intelligence Brief

Jens D Lundgren, MD pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

Portfolio leaders (marketed + Phase 3 / filed)

Therapeutic area mix

• Immunology / Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

1. Arcturus Therapeutics, Inc. · 1 shared drug class
2. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
3. BioNTech SE · 1 shared drug class
4. CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 shared drug class
5. CanSino Biologics Inc. · 1 shared drug class
6. Clover Biopharmaceuticals AUS Pty · 1 shared drug class
7. Federal University of Espirito Santo · 1 shared drug class
8. AIM Vaccine Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Jens D Lundgren, MD:

• Jens D Lundgren, MD pipeline updates — RSS
• Jens D Lundgren, MD pipeline updates — Atom
• Jens D Lundgren, MD pipeline updates — JSON

Cite this brief

Drug Landscape (2026). Jens D Lundgren, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jens-d-lundgren-md. Accessed 2026-06-10.

Related

• Jens D Lundgren, MD full company profile
• All CI briefs
• Build a custom feed